Inclusion Criteria:

1. Patients must have histologically or cytologically confirmed squamous cell carcinoma
of the head and neck with suspected lymph node metastasis. Subjects with
histological confirmation of squamous cell carcinoma from a lymph node biopsy in the
head and neck region for carcinoma of unknown primary would also be eligible.

2. Patient must be scheduled to receive (or have already received) clinical whole body
PET/CT scan from a Siemens Biograph 40 PET/CT scanner as their standard of care
staging.

3. Patient must be scheduled to receive surgical removal of the primary tumor and the
regional lymph nodes. It is preferred that the surgery will occur within 21 days of
research PET imaging.

4. Age >18 years, as head and neck cancer is extremely rare in children.

5. Ability of the patient (or legally authorized representative if applicable) to
understand and the willingness to sign a written informed consent document.

6. Not currently pregnant or nursing: Female subjects must be either surgically sterile
(has had a documented bilateral oophorectomy and/or documented hysterectomy), or post
menopausal (cessation of menses for more than 1 year). If of childbearing potential,
a urine pregnancy test must be performed within the 24 hour period immediately prior
to administration of 18FDG and determined to be negative

Exclusion Criteria:

1. The subject weight will be limited to 250 lbs and below due to the size limitations
of the prototype PET insert device.

2. Subjects who are claustrophobic

3. Subjects with poorly controlled diabetes (fasting blood glucose >200mg/dL)

4. Subjects with prior head/neck surgery or radiation as this may disturb the natural
architecture of the tissues and impede the imaging analysis